Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Absci

Which Healthcare Stock Is the Best Buy Right Now?

Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.

MarketBeat

1 'Strong Buy' Penny Stock to Invest in AI Drug Development

Investors seeking AI-led drug development opportunities can consider this top-rated biotech stock under $5.

Barchart

1 'Strong Buy' Biotech Stock With 132% Upside Potential

Analysts expect this small-cap biotech stock to more than double in value as it integrates AI into its drug development process.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

International Business Times UK

3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

Barchart

AstraZeneca Partners With AI Company to Find Cure For Cancer

Absci, a drug and target discovery company, has been harnessing the power of deep learning AI to develop new and existing disease treatments.

International Business Times UK

Absci's Return On Capital Employed Insights

Absci (NASDAQ:ABSI) brought in sales totaling $819.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 17.2%, resulting in a loss of $29.49 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here's Why Absci Corp Shares Are Falling

Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results.

Benzinga

Absci's Return On Capital Employed Overview

Absci (NASDAQ:ABSI) brought in sales totaling $1.45 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 6.48%, resulting in a loss of $25.17 million.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.